Key words
fluorine - peptide - β-amino acid - α,α-difluoro-β-lactam - 2,2,2-trifluoroethanol
β-Amino acids are considered important non-proteinogenic amino acids and are deliberately
incorporated into peptides to change their physical properties and biological activity.[1] In drug discovery, β-amino acids have been used to mimic natural peptide-based antibiotics
that have high proteolytic stability in vivo.[2] Protease resistance is an intrinsic property of β-amino acids and has been successfully
exploited to produce the aminopeptidase inhibitor, bestatin[3] and the more potent analogue 1
[4] (Figure [1]). We have previously focused on these β-amino acid structures, particularly 3-amino-2-hydroxy-3-phenylpropanoic
acid moiety, which is found in paclitaxel (Taxol®)[5] and docetaxel (Taxotere®).[6] Additionally, we envisioned that a hydroxymethylene group could be replaced by a
difluoromethylene unit, which may be useful because fluoroalkyl group sometimes behaves
like hydroxyl groups in biological assays.[7] However, a convenient approach to synthesize peptide 3 is still very challenging using current peptide chemistry.
Figure 1 a) The structures of bestatin and its more potent analogue 1 and paclitaxel. b) Target compounds 3 and the retrosynthetic strategy.
Regarding the synthesis of β-amino acid-containing peptides, recent progress in ribosome
or enzyme engineering allows β-amino acid incorporation into polypeptides.[8]
[9] However, in most cases, organic synthesis is still required to prepare highly functionalized
β-amino acids and incorporate them into peptides. To date, there have been several
reports on the synthesis of functionalized β-amino acids and related structures,[10] including those with fluorine substituents adjacent to the carbonyl (β2-)[11] or to the amino (β3-)[12] positions. β-Lactam synthon method has been also known for the construction of β-amino
acid substructure.[10a]
[11a]
[c]
[e]
[f]
[13] However, to the best of our knowledge, there are only few examples on the one-pot
synthesis of functionalized β-amino acid-containing peptides, except for conventional
peptide synthesis, which involves sequential, step-by-step condensation reactions
of activated amino acid derivatives.[11c]
[13c] In this context, we hypothesized that α,α-difluoro-β-lactams 2 ought to be a good precursor for the one-pot synthesis of 3 via a ring-opening nucleophilic attack by various amino acids, although the product
would be a diastereomixture.
For this approach, the synthetic drawback remained in the reactivity of both 2 and the amino acid. Particularly, the nucleophilicity of the nitrogen atom in the
amino acid is significantly lower than commonly used amino compounds, so the direct
reaction of 2 and amino acid would be suppressed. To check the reactivity of 2 towards amino acids, 2a was reacted with glycine methyl ester hydrochloride in the presence of N,N-diisopropylethylamine (DIPEA) as a non-nucleophilic base (Table [1]). The desired substrate 2 was synthesized by our previously reported Rh-catalyzed imino-Reformatsky reaction
of ethyl bromodifluoroacetate using diethylzinc in a gram scale reaction.[14]
Table 1 Synthesis of α,α-Difluoro-β-lactam 2a and Solvent Screen for Ring-Opening Peptide Synthesis Using 2a as an α,α-Difluoro-β-amino Acid Unita
|
|
Entry
|
Solvent
|
Time (h)
|
Yield (%)b
3a
|
Recovery (%) 2a
|
|
1
|
DMA
|
20
|
45
|
52
|
|
2
|
NMP
|
24
|
61
|
36
|
|
3
|
DMSO
|
21
|
75
|
23
|
|
4
|
DMF
|
48
|
88
|
6
|
|
5
|
MeOH
|
20
|
92
|
0
|
|
6
|
CF3CH2OH
|
2
|
84
|
0
|
|
7c
|
MeOH
|
4
|
49
|
50
|
a Reaction was done with the concentration of 0.67 M (0.2 mmol/0.3 mL) of 2a.
b Isolated yields.
c TFE and 2a were used in equimolar amounts.
The ring-opening aminolysis with glycine proceeded to give the product of the open-chain
peptide 3a. In this reaction, polar aprotic solvents commonly used in SN2-type reactions seemed to decrease the reactivity and gave 3a with very slow reaction times, which were impractical for use (Table [1], entries 1–4). In contrast, methanol, a protic solvent, accelerated the reaction
to give 3a in 92% yield; however, the reaction rate was still slow (20 h). A dramatic improvement
in reaction efficiency was observed when it was performed in 2,2,2-trifluoroethanol
(TFE) solution; 3a was provided in 84% yield after two hours reaction time. However, when equimolar
amount of TFE was used in methanol, a significant decrease in yield of 3a was observed along with unreacted 2a (entry 7). This reaction was very simple to perform, and there was no need for any
activation process prior to the reaction, suggesting that this new approach was practical
and effective for preparing α,α-difluorinated β-amino acid containing peptides.
With the optimized conditions in hand, the substrate scope of the reaction was examined.
The results are shown in Figure [2]. All the reactions were completed within 2–3 hours. It is noteworthy that this reaction
could accommodate α-amino acids with bulky substituents. Not only simple amino acids,
such as alanine, but also bulkier amino acids, valine, leucine, and isoleucine, all
successfully reacted with 2a to give peptides 3c–e in good yields. Hydroxy groups on aliphatic carbons disturbed the reaction to some
extent, and their yield decreased to around 35% (→ 3f and 3g). However, the less nucleophilic phenolic group did not disturb the reaction process,
and 3h was obtained in good yield. Other aromatic amino acids and basic amino acids, which
were masked amino nucleophiles on the side chain, were also compatible (→ 3i–l). It is worth mentioning that histidine was able to participate in the reaction without
any protection on nitrogen atom to give 3m in good yield. Ester, amido, and sulfide substituents, and even nucleophilic thiol
in the case of cysteine, were compatible with the reaction (→ 3n–s).
Figure 2 Scope of the reaction of 2a with various α-amino acids esters. Isolated yields are shown. a Amino acid ester (1 equiv) and DIPEA (2 equiv) were used. b Histidine methyl ester hydrochloride 2 (2 equiv) and DIPEA (5 equiv) were used. c A complex mixture was obtained, but a trace amount of 3t was detected in 1H and 19F NMR spectra.
Unfortunately, in the case of proline, the reaction was unfavorable, and only a small
amount of the product 3t was observed as the reaction progressed; furthermore, it did not appear to be since
it decomposed in the purification process. In the case of another bulky amino acid,
phenyl glycine, the reaction proceeded but longer reaction time was needed to obtain
3u, which is an analogue of aminopeptidase inhibitor 1, in 81% yield. It is interesting to note that the tripeptide, H-Gly-Gly-Gly-OMe was
able to react with 2a to give 3v in good yield, highlighting the good performance of this reaction as a convenient
method for one-pot peptide synthesis.
To demonstrate the high practical potential of this method, we proceeded to synthesize
the tripeptide 6 that contained α,α-difluoro-β-amino acid unit between two glycine terminals. As shown
in Scheme [1], N-PMP-α,α-difluoro-β-lactam (2b) was used instead of 2a to obtain a free nitrogen atom for consequent peptide elongation. As expected, the
reaction of 2b with H-Gly-OMe occurred in the same manner, and peptide 4 was obtained. The crude product 4 was treated with ceric ammonium nitrate to remove the PMP group and to give 5 in good yield (from 2b).[15] For the following peptide elongation at the N-terminus of 5, Fmoc-Gly-OH was condensed with 1-hydroxybenzotriazole (HOBt) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC) to give 6 in good yield.[11d]
[16] This reaction scheme exhibits the potential utility of our method by showing its
capability of preparing polypeptides containing an α,α-difluoro-β-amino acid unit
at the desired position.
Scheme 1 Tripeptide synthesis using 2b as the β-amino acid synthon with an α,α-difluoro unit
Scheme 2 Mechanistic study based on the reaction rates between TFE and methanol solutions.
a The conversion was confirmed by TLC analysis, in which 2a had disappeared completely and any other spot arising from 2a was not observed except for the formation of 7 or 8.
To elucidate the reaction mechanism, we tried to understand how TFE accelerated the
reaction between 2a and the α-amino acids. For this purpose, a kinetic study of the reaction was performed
in both the TFE and methanol solution (Scheme [2]). When 2a was dissolved in TFE or methanol, respectively, the ring-opening alcoholysis of 2a occurred at almost the same rate in both cases. After confirming that both conversions
to TFE ester 7 or methyl ester 8 were completed in two hours (monitored by TLC), H-Gly-OMe and DIPEA were added to
each solution to take place the subsequent aminolysis.[17] Interestingly, large differences were observed in the reaction rate; the aminolysis
in TFE solution was obviously faster than that in methanol solution, and gave 3a in 72% yield (compared to 26% in methanol solution). The acceleration effect could
be attributed to the TFE group being a much better leaving group for aminolysis, because
of the existence of a strong electronegative trifluoromethyl group; pK
a (TFE) = 12 versus pK
a (MeOH) = 16.[18] In addition, the moderate acidity of TFE could work as an acidic catalyst for aminolysis
process. We consequently ascribed the rate acceleration in TFE solution to the synergistic
effects of an enhanced leaving group and acid catalysis, both resulting from TFE.
In conclusion, we have developed a convenient method for the synthesis of β-amino
acid peptides containing an α,α-difluoromethylene unit by using α,α-difluoro-β-lactams
2a and 2b. This ring-opening reaction allows access to a wide range of fluorinated β-amino
acid peptides. Most α-amino acids, except for proline, were successfully used in this
transformation to provide the fluorinated dipeptides in good yields. Additionally,
the reaction mechanism was examined by comparing the reactivity in TFE and methanol
solutions, which demonstrated the activation process in TFE. Further studies, for
example, on the synthesis of particular peptide-based pharmaceuticals and analogues
in diastereomerically pure form, are ongoing in our laboratory with enantiomerically
pure 2.
NMR spectra were obtained from a solution in DMSO-d
6 or CDCl3 using 400 MHz for 1H NMR, 100 MHz for 13C, 376 MHz for 19F NMR. DMSO-d
6 solution of NMR samples were recorded at 40 °C, unless noted otherwise. Chemical
shifts of 1H and 13C NMR are reported in ppm downfield of TMS (1H = 0.00) and DMSO-d
6 (1H δ = 2.49, 13C δ = 39.5). Chemical shifts of 19F NMR are reported in ppm from CFCl3 as an internal standard. 13C NMR spectra were obtained with 1H decoupling. All data are reported as follows: chemical shifts, multiplicity (standard
abbreviations), coupling constants (Hz), and relative integration value. The measurement
of all NMR spectra were obtained from the diastereomixture of peptide products. HRMS
experiments were measured on a double-focusing mass spectrometer with an ionization
mode of EI or positive-FAB using glycerin as a matrix. All experiments were carried
out under an argon atmosphere in flame-dried glassware using standard inert techniques
for introducing reagents and solvents unless otherwise noted. All commercially available
materials were used as received without further purification. Solvents were heated
to reflux over CaH2 (DMF) and Mg metal (TFE and MeOH) under an argon atmosphere and collected by distillation
just before use.
Note: All aromatic carbons could not be observed in 13C NMR spectra of the products 3a–v and 6 reported below, probably due to overlapping.
α,α-Difluoro-β-lactams 2a,b; General Procedure
α,α-Difluoro-β-lactams 2a,b; General Procedure
Ethyl bromodifluoroacetate (20 mmol) and the corresponding imine (10 mmol) were added
to a solution of RhCl(PPh3)3 (1 mol%) in THF (60 mL) at 0 °C and stirred for 0.5 h. A 1.0 M solution of Et2Zn in hexane (30 mmol) was slowly added to the solution via a dropping funnel, and
then the whole mixture was stirred at the same temperature. The reaction was quenched
with aq 10% HCl, the mixture was extracted with EtOAc, and the combined extracts were
washed with brine and dried (MgSO4). The solvent was removed in vacuo and the residue was purified by flash column chromatography
to give the corresponding α,α-difluoro-β-lactams 2a,b.
Ring-Opening Peptide Synthesis; General Procedure
Ring-Opening Peptide Synthesis; General Procedure
To a vial containing difluoro-β-lactam 2a (51.9 mg, 0.2 mmol) and amino acid ester hydrochloride (0.4 mmol) in TFE (0.3 mL)
was added DIPEA (0.10 mL, 0.6 mmol) at r.t. and the mixture was stirred at r.t. for
2 h. The mixture was poured into H2O and then extracted with EtOAc. The combined organic phases were washed with brine,
dried (MgSO4), and concentrated in vacuo. The crude mixture was purified with flash column chromatography
to give the pure product 3.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-glycinate (3a)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-glycinate (3a)
Eluent: EtOAc/hexane (3:7); yield: 58.5 mg (84%); colorless solid; mp 153.0–154.0
°C; Rf
= 0.2 (EtOAc/hexane, 3:7).
1H NMR (DMSO-d
6, 400 MHz): δ = 9.07 (m, 1 H), 7.52 (d, J = 7.2 Hz, 2 H), 7.36–7.29 (m, 3 H), 7.02 (t, J = 8.0 Hz, 2 H), 6.73 (d, J = 7.6 Hz, 2 H), 6.55 (t, J = 7.4 Hz, 1 H), 6.27 (d, J = 10.4 Hz, 1 H), 5.28 (ddd, J = 19.5, 10.4, 9.4 Hz, 1 H), 3.88 (m, 2 H), 3.58 (s, 3 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 169.1, 163.3 (t, J = 28.8 Hz), 146.6, 135.2, 128.7, 128.6, 128.0, 117.2, 115.9 (dd, J = 260.3, 254.3 Hz), 113.7, 58.0 (dd, J = 27.5, 21.7 Hz), 51.7, 40.7.
19F NMR (DMSO-d
6, 376 MHz): δ = –107.0 (dd, J = 252.9, 9.4 Hz, 1 F), –117.3 (dd, J = 252.9, 19.5 Hz, 1 F).
MS (EI): m/z = 348 [M]+.
HRMS (EI): m/z [M]+ calcd for C18H18F2N2O3: 348.1285; found: 348.1288.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-alaninate (3b)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-alaninate (3b)
Eluent: EtOAc/hexane (3:7); yield: 56.1 mg (77%); dr 1:1.3; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.00 (t, J = 6.0 Hz, 1 H), 7.53–7.50 (m, 2 H), 7.36–7.26 (m, 3 H), 7.04–7.00 (m, 2 H), 6.75–6.71
(m, 2 H), 6.57–6.53 (m, 1 H), 6.30–6.27 (m, 1 H), 5.34–5.22 (m, 1 H), 4.37–4.28 (m,
1 H), 3.57 (s, 1.7 H), 3.54 (s, 1.3 H), 1.27 (d, J = 6.8 Hz, 1.3 H), 1.19 (d, J = 6.8 Hz, 1.7 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 171.7, 162.6 (t, J = 28.9 Hz), 162.5 (t, J = 28.9 Hz), 146.6, 146.5, 135.5, 135.5, 135.1, 135.1, 128.6, 128.6, 128.0, 117.1,
117.0 115.9 (dd, J = 257.2, 256.2 Hz), 115.8 (dd, J = 257.2, 254.3 Hz), 113.4, 58.1 (t, J = 21.2 Hz), 57.9 (t, J = 22.2 Hz), 51.8, 51.8, 47.7, 47.6, 16.3.
19F NMR (DMSO-d
6, 376 MHz): δ = –107.5 (dd, J = 251.4, 9.4 Hz, 0.43 F), –108.9 (dd, J = 250.3, 10.5 Hz, 0.59 F), –115.9 (dd, J = 250.7, 18.8 Hz, 0.58 F), –117.1 (dd, J = 251.1, 19.9 Hz, 0.42 F).
MS (EI): m/z = 362 [M]+.
HRMS (EI): m/z [M]+ calcd for C19H20F2N2O3: 362.1442; found: 362.1446.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-valinate (3c)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-valinate (3c)
Eluent: EtOAc/hexane (3:7); yield: 56.6 mg (72%); dr 1:1.2; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.83 (d, J = 8.2 Hz, 0.54 H), 8.66 (d, J = 8.4 Hz, 0.46 H), 7.55–7.52 (m, 2 H), 7.35–7.26 (m, 3 H), 7.03–7.00 (m, 2 H), 6.75–6.70
(m, 2 H), 6.56–6.53 (m, 1 H), 6.35 (d, J = 11.0 Hz, 0.47 H), 6.34 (d, J = 10.4 Hz, 0.56 H), 5.40 (ddd, J = 19.7, 10.4, 9.7 Hz, 0.56 H), 5.30 (ddd, J = 22.2, 11.0, 7.3 Hz, 0.47 H), 4.21 (dd, J = 8.4, 7.8 Hz, 0.46 H), 4.17 (dd, J = 8.2, 7.8 Hz, 0.54 H), 3.6 (s, 1.56 H), 3.57 (s, 1.32 H), 2.16–1.98 (m, 1 H), 0.85
(dd, J = 15.6, 6.9 Hz, 2.9 H), 0.74 (dd, J = 11.4, 6.9 Hz, 3.3 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 170.9, 170.8, 163.1 (t, J = 28.9 Hz), 162.9 (t, J = 29.5 Hz), 146.5, 146.3, 135.3, 135.1, 128.7, 128.6, 128.5, 127.9, 127.9, 117.1,
117.0, 115.9 (dd, J = 256.7, 253.3 Hz), 115.8 (dd, J = 256.2, 255.3 Hz), 113.5, 113.4, 58.2–57.5 (m), 57.8, 51.7, 29.7, 29.5, 18.7, 18.6,
18.2, 18.1.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.2 (dd, J = 250.7, 7.3 Hz, 0.47 F), –107.9 (dd, J = 251.4, 9.7 Hz, 0.56 F), –115.3 (dd, J = 251.4, 19.7 Hz, 0.56 F), –117.5 (dd, J = 250.7, 22.2 Hz, 0.47 F).
MS (EI): m/z = 390 [M]+.
HRMS (EI): m/z [M]+ calcd for C21H24F2N2O3: 390.1755; found: 390.1758.
Methyl [2,2-difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-leucinate (3d)
Methyl [2,2-difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-leucinate (3d)
Eluent: EtOAc/hexane (1:4); yield: 57.0 mg (70%); dr 1:1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.98 (d, J = 8.2 Hz, 0.5 H), 8.91 (d, J = 7.8 Hz, 0.5 H), 7.53–7.51 (m, 2 H), 7.36–7.27 (m, 3 H), 7.04–7.00 (m, 2 H), 6.72–6.70
(m, 2 H), 6.56–6.53 (m, 1 H), 6.34 (d, J = 10.5 Hz, 0.5 H), 6.27 (d, J = 10.5 Hz, 0.5 H), 5.37–5.22 (m, 1 H), 4.38–4.28 (m, 1 H), 3.60 (s, 1.5 H), 3.56
(s, 1.5 H), 1.72–1.20 (m, 3 H), 0.80 (d, J = 6.0 Hz, 1.5 H), 0.68 (d, J = 6.4 Hz, 3 H), 0.62 (d, J = 6.4 Hz, 1.5 H).
13C{1H} NMR (acetone-d
6, 100 MHz): δ = 172.8, 172.7, 164.2 (t, J = 28.5 Hz), 164.0 (t, J = 28.5 Hz), 147.6, 147.3, 136.3, 136.2, 136.1, 129.7, 129.6, 129.2, 129.1, 129.1,
118.7, 118.6, 117.2 (dd, J = 260.9, 257.0 Hz), 117.0 (dd, J = 260.6, 254.8 Hz), 114.6, 60.1 (dd, J = 25.5, 22.1 Hz), 59.7 (dd, J = 27.9, 22.1 Hz), 52.5, 52.5, 51.5, 51.4, 40.9, 40.7, 25.0, 24.9, 23.3, 23.2, 21.5,
21.3.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.7 (dd, J = 250.3, 8.3 Hz, 0.5 F), –109.4 (dd, J = 250.7, 10.8 Hz, 0.5 F), –115.0 (dd, J = 250.7, 18.8 Hz, 0.5 F), –117.9 (dd, J = 250.3, 21.3 Hz, 0.5 F).
MS (EI): m/z = 404 [M]+.
HRMS (EI): m/z [M]+ calcd for C22H26F2N2O3: 404.1911; found: 404.1912.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-isoleucinate (3e)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-isoleucinate (3e)
Eluent: EtOAc/hexane (3:7); yield: 65.6 mg (81%); dr 1:1.1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.86 (d, J = 8.2 Hz, 0.5 H), 8.67 (d, J = 8.2 Hz, 0.42 H), 7.54–7.51 (m, 2 H), 7.35–7.28 (m, 3 H), 7.03–6.99 (m, 2 H), 6.73–6.69
(m, 2 H), 6.56–6.52 (m, 1 H), 6.37–6.32 (m, 1 H), 5.34–5.45 (m, 1 H), 5.40 (ddd, J = 19.8, 10.8, 9.5 Hz, 0.52 H), 5.28 (ddd, J = 21.9, 11.0, 7.8 Hz, 0.48 H), 4.25–4.16 (m, 1 H), 3.61 (s, 1.48 H), 3.57 (s, 1.36
H), 1.89–1.74 (m, 1 H), 1.45–0.91 (m, 2 H), 0.81–0.62 (m, 6 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 171.1, 170.9, 162.9 (t, J = 29.4 Hz), 162.8 (t, J = 29.4 Hz), 146.5, 146.3, 135.3, 135.1, 128.7, 128.6, 128.6, 128.5, 128.0, 127.9,
117.1, 117.0, 115.9 (dd, J = 259.1, 253.4 Hz), 115.8 (dd, J = 257.2, 255.3 Hz), 113.4, 113.4, 57.8 (dd, J = 27.9, 22.1 Hz), 57.7 (dd, J = 28.4, 21.2 Hz), 56.7, 56.6, 51.7, 39.50, 35.8, 35.7, 24.5, 24.4, 15.0, 14.9, 10.6,
10.3.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.4 (dd, J = 250.3, 7.8 Hz, 0.48 F), –107.8 (dd, J = 251.4, 9.5 Hz, 0.52 F), –115.5 (dd, J = 251.1, 19.8 Hz, 0.52 F), –117.5 (dd, J = 250.3, 21.9 Hz, 0.48 F).
MS (EI): m/z = 404 [M]+.
HRMS (EI): m/z [M]+ calcd for C22H26F2N2O3: 404.1911; found: 404.1919.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-serinate (3f)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-serinate (3f)
Eluent: EtOAc/hexane (1:1); yield: 26.3 mg (35%); dr 1:1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.77–8.75 (m, 1 H), 7.59–7.56 (m, 2 H), 7.40–7.31 (m, 3 H), 7.08–7.04
(m, 2 H), 6.79–6.76 (m, 2 H), 6.61–6.57 (m, 1 H), 6.36–6.33 (m, 1 H), 5.42–5.30 (m,
1 H), 5.10–5.04 (m, 1 H), 4.46–4.39 (m, 1 H), 3.80–3.63 (m, 2 H), 3.61 (s, 1.5 H),
3.59 (s, 1.5 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 169.9, 169.8, 163.2–162.6 (m), 146.6, 146.5, 135.2, 135.1, 128.7,
128.6, 128.6, 128.0, 117.2, 117.1, 115.9 (dd, J = 258.6, 254.4 Hz), 115.8 (dd, J = 259.1, 254.3 Hz), 113.6, 113.5, 60.7, 58.1 (dd, J = 27.2, 21.7 Hz), 57.9 (dd, J = 26.7, 21.8 Hz), 54.9, 54.8, 51.9.
19F NMR (DMSO-d
6, 376 MHz): δ = –107.1 (dd, J = 251.4, 8.7 Hz, 0.5 F), –107.3 (dd, J = 251.9, 9.4 Hz, 0.5 F), –116.7 (dd, J = 251.4, 19.7 Hz, 0.5 F), –117.1 (dd, J = 251.9, 20. 3 Hz, 0.5 F).
MS (EI): m/z = 378 [M]+.
HRMS (EI): m/z [M]+ calcd for C19H20F2N2O4: 378.1391; found: 378.1389.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-threoninate (3g)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-threoninate (3g)
Eluent: EtOAc/hexane (3:2); yield: 35.0 mg (45%); dr 1:1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.39 (d, J = 8.7 Hz, 0.5 H), 8.26 (d, J = 8.2 Hz, 0.5 H), 7.61–7.59 (m, 2 H), 7.42–7.33 (m, 3 H), 7.08–7.05 (m, 2 H), 6.81–6.76
(m, 2 H), 6.61–6.58 (m, 1 H), 6.46–6.42 (m, 1 H), 5.48–5.32 (m, 1 H), 5.12 (d, J = 6.4 Hz, 0.5 H), 5.02 (d, J = 6.4 Hz, 0.5 H), 4.40 (dd, J = 14.4, 8.4 Hz, 0.5 H), 4.39 (dd, J = 14.1, 8.7 Hz, 0.5 H), 4.25–4.13 (m, 1 H), 3.65 (s, 1.5 H), 3.64 (s, 1.5 H), 1.10
(d, J = 6.4 Hz, 1.5 H), 0.92 (d, J = 6.4 Hz, 1.5 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 169.9, 169.8, 163.2 (t, J = 28.9 Hz), 146.6, 146.4, 135.2, 135.2, 135.0, 128.7, 128.6, 128.6, 127.9, 117.1,
117.0, 116.1 (dd, J = 257.7, 254.8 Hz), 116.0 (dd, J = 260.6, 255.7 Hz), 113.6, 66.0, 65.9, 58.0, 57.9 (dd, J = 26.0, 21.2 Hz), 57.6 (dd, J = 28.4, 22.2 Hz), 51.9, 51.9, 19.7, 19.5.
19F NMR (DMSO-d
6, 376 MHz): δ = –105.60 (dd, J = 250.3, 6.9 Hz, 0.5 F), –108.45 (dd, J = 251.4, 10.5 Hz, 0.5 F), –115.47 (dd, J = 251.4, 19.5 Hz, 0.5 F), –118.66 (dd, J = 250.3, 22.8 Hz, 0.5 F).
MS (EI): m/z = 392 [M]+.
HRMS (EI): m/z [M]+ calcd for C20H22F2N2O4: 392.1548; found: 392.1549.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-tyrosinate (3h)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-tyrosinate (3h)
Eluent: EtOAc/hexane (3:7); yield: 75.1 mg (83%); dr 1:1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 9.13 (br s, 0.5 H), 9.12 (br s, 0.5 H), 8.96 (d, J = 7.3 Hz, 0.5 H), 8.94 (d, J = 7.3 Hz, 0.5 H), 7.50–7.28 (m, 5 H), 7.05–6.88 (m, 4 H), 6.72–6.54 (m, 5 H), 6.26
(d, J = 9.2 Hz, 0.5 H), 6.23 (d, J = 8.6 Hz, 0.5 H), 5.28 (ddd, J = 18.8, 10.5, 8.6 Hz, 1 H), 5.21 (ddd, J = 19.5, 9.2, 8.3 Hz, 1 H), 4.43–4.37 (m, 1 H), 3.54 (s, 1.5 H), 3.50 (s, 1.5 H),
3.00–2.81 (m, 2 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 170.9, 170.8, 162.8 (t, J = 28.9 Hz), 162.7 (t, J = 28.9 Hz), 156.0, 155.9, 146.6, 146.5, 135.2, 135.1, 129.9, 129.8, 128.7, 128.7,
128.6, 128.0, 127.9, 126.9, 126.8, 117.2, 117.1, 115.8 (dd, J = 259.1, 254.3 Hz), 115.7 (dd, J = 258.7, 254.5 Hz), 115.1, 115.0, 113.6, 113.5, 58.0 (dd, J = 27.0, 22.2 Hz), 54.2, 54.1, 51.8, 51.8, 35.3, 35.2.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.9 (dd, J = 253.2, 8.3 Hz, 0.5 F), –108.3 (dd, J = 251.1, 10.5 Hz, 0.5 F), –115.9 (dd, J = 251. 4, 18.8 Hz, 0.5 F), –116.4 (dd, J = 252.9, 19.5 Hz, 0.5 F).
MS (EI): m/z = 454 [M]+.
HRMS (EI): m/z [M]+ calcd for C25H24F2N2O4: 454.1704; found: 454.1705.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-phenylalaninate (3i)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-phenylalaninate (3i)
Eluent: EtOAc/hexane (3:7); yield: 64.9 mg (74%); dr 1:1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 9.11 (d, J = 7.8 Hz, 1 H), 7.55–7.06 (m, 12 H), 6.78–6.60 (m, 3 H), 6.30 (d, J = 10.6 Hz, 0.5 H), 6.28 (d, J = 10. 3 Hz, 0.5 H), 5.33 (ddd, J = 20.2, 10.6, 8.7 Hz, 0.5 H), 5.26 (ddd, J = 18.8, 10.3, 10.1 Hz, 0.5 H), 4.57–4.51 (m, 1 H), 3.60 (s, 1.5 H), 3.55 (s, 1.5
H), 3.10 (dd, J = 14.0, 5.3 Hz, 0.5 H), 3.06 (dd, J = 13.9, 5.2 Hz, 0.5 H), 2.99 (dd, J = 14.0, 9.3 Hz, 0.5 H), 2.95 (dd, J = 13.9, 9.1 Hz, 0.5 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 170.7, 162.8 (t, J = 28.9 Hz), 162.8 (t, J = 29.5 Hz), 146.5, 136.9, 136.8, 135.1, 135.0, 128.9, 128.8, 128.6, 128.6, 128.5,
128.1, 128.0, 127.9, 127.9, 126.4, 126.3, 117.1, 117.1, 115.8 (dd, J = 260.1, 254.3 Hz), 115.6 (dd, J = 260.1, 254.3 Hz), 113.6, 113.5, 57.9 (dd, J = 27.0, 22.1 Hz), 57.9 (dd, J = 28.3, 22.1 Hz), 53.8, 53.7, 51.9, 51.8, 35.9, 35.8.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.67 (dd, J = 253.6, 8.7 Hz, 0.5 F), –107.94 (dd, J = 251.4, 10.1 Hz, 0.5 F), –116.3 (dd, J = 251.4, 18.8 Hz, 0.5 F), –116.6 (dd, J = 253.6, 20.2 Hz, 0.5 F).
MS (EI): m/z = 438 [M]+.
HRMS (EI): m/z [M]+ calcd for C25H24F2N2O3: 438.1755; found: 438.1764.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-tryptophanate (3j)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-tryptophanate (3j)
Eluent: EtOAc/hexane (3:7); yield: 104.2 mg (73%); dr 1:1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 10.8 (s, 0.5 H), 10.7 (s, 0.5 H), 9.0 (d, J = 7.3 Hz, 0.5 H), 8.9 (d, J = 7.8 Hz, 0.5 H), 7.5–6.9 (m, 12 H), 6.7–6.5 (m, 3 H), 6.3 (d, J = 10.5 Hz, 1 H), 5.2–5.3 (m, 1 H), 4.5 (m, 1 H), 3.5 (s, 1.5 H), 3.5 (s, 1.5 H),
3.3–3.1 (m, 2 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 171.1, 171.0, 162.7 (t, J = 29.0 Hz), 146.6, 146.5, 136.1, 136.0, 135.2, 135.1, 135.0, 135.0, 128.6, 128.5,
128.0, 127.9, 127.9, 126.9, 126.8, 123.6, 123.4, 120.9, 120.9, 118.4, 118.3, 117.8,
117.7, 117.1, 117.1, 115.8 (dd, J = 259.2, 254.9 Hz), 115.8 (dd, J = 259.2, 255.0 Hz), 113.5, 113.4, 111.4, 111.3, 109.1, 109.0, 58.1 (dd, J = 26.7, 21.9 Hz), 53.3, 53.2, 51.8, 51.8, 26.4, 26.3.
19F NMR (DMSO-d
6, 376 MHz): δ = –107.98 (dd, J = 251.4, 10.1 Hz, 0.5 F), –109.19 (dd, J = 250.7, 10.8 Hz, 0.5 F), –115.3 (dd, J = 250.3, 18.3 Hz, 0.5 F), –116.0 (dd, J = 251.3, 19.2 Hz, 0.5 F).
MS (EI): m/z = 477 [M]+.
HRMS (EI): m/z [M]+ calcd for C27H25F2N3O3: 477.1864; found: 477.1868.
Methyl N
6-(tert-Butoxycarbonyl)-N
2-[2,2-difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-lysinate (3k)
Methyl N
6-(tert-Butoxycarbonyl)-N
2-[2,2-difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-lysinate (3k)
Eluent: EtOAc/hexane (3:7); yield: 76.2 mg (73%); dr 1:1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.9 (d, J = 7.8 Hz, 0.5 H), 8.8 (d, J = 8.2 Hz, 0.5 H), 7.5 (m, 2 H), 7.4–7.3 (m, 3 H), 7.0–6.9 (m, 2 H), 6.7 (m, 2 H),
6.6 (br s, 1 H), 6.5 (m, 2 H), 6.3 (m, 1 H), 5.4–5.2 (m, 1 H), 4.3–4.2 (m, 1 H), 3.6
(s, 1.5 H), 3.5 (s, 1.5 H), 2.9–2.7 (m, 2 H), 1.8–1.5 (m, 2 H), 1.4 (s, 9 H), 1.3–0.9
(m, 4 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 171.4, 171.3, 162.9 (t, J = 28.9 Hz), 162.9 (t, J = 28.9 Hz), 155.4, 146.6, 146.4, 135.2, 135.2, 135.1, 128.7, 128.6, 128.0, 117.1,
117.1, 115.9 (dd, J = 257.5, 256.7 Hz), 115.8 (dd, J = 261.0, 253.4 Hz), 113.4, 77.2, 58.0 (dd, J = 26.4, 21.7 Hz), 57.8 (dd, J = 27.8, 21.5 Hz), 52.1, 52.0, 51.8, 51.8, 39.2,a,b 29.9,a 29.9,a 28.9,a 28.7,a 28.1, 22.4,a 22.3.a a These signals were observed as reverse image in DEPT 135. b This signal overlapped with solvent peaks (DMSO-d
6).
19F NMR (DMSO-d
6, 376 MHz): δ = –107.0 (dd, J = 250.5, 6.1 Hz, 0.5 F), –109.4 (dd, J = 251.2, 9.4 Hz, 0.5 F), –115.1 (dd, J = 251.2, 17.7 Hz, 0.5 F), –117.3 (dd, J = 250.5, 21.0 Hz, 0.5 F).
MS (EI): m/z = 519 [M]+.
HRMS (EI): m/z [M]+ calcd for C27H35F2N3O5: 519.2545; found: 519.2546.
Methyl N
2-[2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-N
ω-nitro-l-argininate (3l)
Methyl N
2-[2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-N
ω-nitro-l-argininate (3l)
Amino acid (1 equiv) and DIPEA (2 equiv) were used; eluent: EtOAc/hexane (4:1); yield:
80.5 mg (82%); dr 1:1.2; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.9 (m, 1 H), 8.4 (s, 1 H), 7.9 (s, 2 H), 7.5 (m, 2 H), 7.4–7.3 (m,
3 H), 7.0 (m, 2 H), 6.7–6.5 (m, 3 H), 6.3 (m, 1 H), 5.3–5.2 (m, 1 H), 4.3–4.2 (m,
1 H), 3.6 (s, 1.6 H), 3.5 (s, 1.4 H), 3.1–2.9 (m, 2 H), 1.9–1.2 (m, 4 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 171.2, 171.1, 163.0 (t, J = 28.9 Hz), 162.9 (t, J = 29.5 Hz), 159.2, 159.2, 146.6, 146.4, 135.2, 135.2, 135.1, 135.1, 128.7, 128.6,
128.0, 117.1, 117.1, 116.0 (dd, J = 253.3, 248.1 Hz), 113.4, 113.4, 58.3–57.6 (m), 51.9, 51.9, 51.8, 39.9,a,b 27.4,a 27.3,a 24.6.a a These signals were observed as reverse image in DEPT 135. b This signal overlapped with solvent peaks (DMSO-d
6).
19F NMR (DMSO-d
6, 376 MHz): δ = –107.2 (d, J = 250.4 Hz, 0.4 F), –109.7 (dd, J = 249.5, 10.8 Hz, 0.6 F), –114.9 (dd, J = 249.5, 17.7 Hz, 0.6 F), –117.1 (dd, J = 250.4, 20.2 Hz, 0.4 F).
MS (FAB): m/z = 493 [M + H]+.
HRMS (FAB): m/z [M + H]+ calcd for C22H27F2N6O5: 493.2011; found: 493.2014.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-histidinate (3m)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-histidinate (3m)
The reaction was carried out on a 0.3 mmol scale. Histidine methyl ester 2 HCl (2
equiv) and DIPEA (5 equiv) were used; eluent: EtOAc/hexane (3:7) → EtOH/CHCl3 (5:95); yield: 73.3 mg (80%); dr 1:1.1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 11.8 (s, 1 H), 9.1 (d, J = 7.8 Hz, 0.5 H), 9.1 (d, J = 7.8 Hz, 0.5 H), 7.6–7.3 (m, 6 H), 7.0 (m, 2 H), 6.8 (s, 0.5 H), 6.7 (m, 2.5 H),
6.5 (m, 1 H), 6.3 (m, 1 H), 5.3–5.2 (m, 1 H), 4.6–4.4 (m, 1 H), 3.51 (s, 1.5 H), 3.5
(s, 1.5 H), 2.9 (d, J = 6.4 Hz, 2 H), 2.9 (d, J = 6.4 Hz, 2 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 170.6, 162.7 (t, J = 28.9 Hz), 162.6 (t, J = 28.6 Hz), 146.6, 146.5, 135.2, 135.1, 135.0, 134.9, 134.9, 128.6, 128.6, 128.6,
128.6, 127.9, 117.1, 117.0, 115.8 (dd, J = 259.6, 256.3 Hz), 113.5, 58.1 (dd, J = 27.0, 23.1 Hz), 57.9 (dd, J = 27.0, 23.1 Hz), 52.5, 52.4, 51.8, 28.4.
19F NMR (DMSO-d
6, 376 MHz): δ = –107.3 (dd, J = 252.1, 8.7 Hz, 0.47 F), –108.1 (dd, J = 251.8, 9.2 Hz, 0.53 F), –116.34 (dd, J = 251.8, 18.8 Hz, 0.53 F), –117.21 (dd, J = 252.1, 19.9 Hz, 0.47 F).
MS (EI): m/z = 428 [M]+.
HRMS (EI): m/z [M]+ calcd for C22H22F2N4O3: 428.1660; found: 428.1668.
Di-tert-butyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-aspartate (3n)
Di-tert-butyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-aspartate (3n)
Eluent: EtOAc/hexane (1:9); yield: 58.0 mg (57%); dr 1:1.1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.9 (m, 1 H), 7.5 (m, 2 H), 7.3–7.2 (m, 3 H), 7.0 (m, 2 H), 6.7 (m,
2 H), 6.5 (m, 1 H), 6.3 (d, J = 11.0 Hz, 1 H), 5.3–5.2 (m, 1 H), 4.5 (dd, J = 15.0, 6.7 Hz, 0.5 H), 4.5 (dd, J = 13.8, 6.5 Hz, 0.5 H), 2.7–2.6 (m, 1 H), 2.5–2.4 (m, 1 H),a 1.3 (s, 4.5 H), 1.3 (s, 4.5 H), 1.3 (s, 4.5 H), 1.3 (s, 4.5 H). a This signal overlapped with solvent peaks (DMSO-d
6).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 168.8, 168.7, 168.6, 162.6 (t, J = 28.9 Hz), 162.5 (t, J = 28.9 Hz), 146.6, 146.5, 135.2, 135.1, 128.7, 128.5, 128.0, 117.19, 115.8 (dd, J = 260.1, 254.3 Hz), 115.8 (dd, J = 259.6, 254.7 Hz), 113.7, 113.6, 81.3, 81.3, 80.5, 80.4, 58.2–57.5 (m), 49.4, 49.3,
36.4, 36.3, 27.5, 27.5, 27.3, 27.3.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.5 (dd, J = 253.2, 8.3 Hz, 0.48 F), –107.6 (dd, J = 252.1, 9.4 Hz, 0.52 F), –116.9 (dd, J = 252.1, 19.5 Hz, 0.52 F), –117.5 (dd, J = 253.2, 20.9 Hz, 0.48 F).
MS (EI): m/z = 504 [M]+.
HRMS (EI): m/z [M]+ calcd for C27H34F2N2O5: 504.2436; found: 504.2439.
tert-Butyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-asparaginate (3o)
tert-Butyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-asparaginate (3o)
Eluent: MeOH/CHCl3 (5:95); yield: 28.8 mg (31%); dr 1:1.2; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.7 (m, 1 H), 7.4 (m, 2 H), 7.3–7.2 (m, 4 H), 6.9 (m, 2 H), 6.8 (br
d, J = 21.5 Hz, 1 H), 6.6 (m, 2 H), 6.5 (m, 1 H), 6.2 (d, J = 10.6 Hz, 0.45 H), 6.2 (d, J = 10.4 Hz, 0.55 H), 5.2 (ddd, J = 20.2, 10.4, 9.6 Hz, 1 H), 4.5–4.4 (m, 1 H), 2.5–2.3 (m, 2 H),a 1.3 (s, 9 H). a This signal overlapped with solvent peaks (DMSO-d
6).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 171.1, 171.0, 169.1, 162.4 (t, J = 28.9 Hz), 162.3 (t, J = 28.9 Hz), 146.6, 146.5, 135.2, 135.1, 128.7, 128.7, 128.6, 128.0, 117.2, 115.9
(dd, J = 259.1, 255.3 Hz), 115.9 (dd, J = 260.6, 253.8 Hz), 113.7, 113.6, 80.9, 58.1 (dd, J = 26.7, 22.3 Hz), 57.8 (dd, J = 28.0, 21.8 Hz), 49.6, 49.5, 35.9, 35.9, 27.4.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.6 (dd, J = 252.3, 8.7 Hz, 0.45 F), –108.0 (dd, J = 251.3, 10.1 Hz, 0.55 F), –116.5 (dd, J = 251.3, 19.1 Hz, 0.55 F), –117.8 (dd, J = 252.3, 20.6 Hz, 0.45 F).
MS (EI): m/z = 447 [M]+.
HRMS (EI): m/z [M]+ calcd for C23H27F2N3O4: 447.1970; found: 447.1974.
5-tert-Butyl 1-Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-glutamate (3p)
5-tert-Butyl 1-Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-glutamate (3p)
Eluent: EtOAc/hexane (1:4); yield: 72.4 mg (76%); dr 1:1.1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 9.0 (d, J = 8.2 Hz, 0.52 H), 8.9 (d, J = 8.2 Hz, 0.48 H), 7.5 (m, 2 H), 7.4–7.3 (m, 3 H), 7.0 (m, 2 H), 6.7 (m, 2 H), 6.5
(m, 1 H), 6.3 (d, J = 10.6 Hz, 0.52 H), 6.3 (d, J = 10.6 Hz, 0.48 H), 5.4–5.2 (m, 1 H), 4.4–4.3 (m, 1 H), 3.6 (s, 1.57 H), 3.6 (s,
1.43 H), 2.3–1.7 (m, 4 H), 1.3 (s, 4.71 H), 1.3 (s, 4.28 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 171.2, 171.2, 171.0, 170.9, 162.9 (t, J = 28.9 Hz), 162.9 (t, J = 29.0 Hz), 146.6, 146.4, 135.2, 135.2, 135.0, 128.7, 128.7, 128.6, 128.0, 117.1,
117.1, 115.9 (dd, J = 261.0, 255.9 Hz), 115.9 (dd, J = 261.4, 253.4 Hz), 113.5, 113.4, 79.6, 58.1 (dd, J = 26.0, 22.2 Hz), 57.9 (dd, J = 28.2, 21.9 Hz), 51.9, 51.92, 5.17, 30.7, 30.6, 27.6, 25.6, 25.5.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.8 (dd, J = 251.3, 8.3 Hz, 0.48 F), –109.5 (dd, J = 250.7, 10.8 Hz, 0.52 F), –115.0 (dd, J = 250.7, 18.1 Hz, 0.52 F), –117.7 (dd, J = 251.3, 21.0 Hz, 0.48 F).
MS (EI): m/z = 476 [M]+.
HRMS (EI): m/z [M]+ calcd for C25H30F2N2O5: 476.2123; found: 476.2124.
tert-Butyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-glutaminate (3q)
tert-Butyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-glutaminate (3q)
Eluent: EtOAc/hexane (3:2): yield: 72.2 mg (76%); dr 1:1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.9 (d, J = 7.1 Hz, 0.5 H), 8.9 (d, J = 7.1 Hz, 0.5 H), 7.5 (m, 2 H), 7.4–7.2 (m, 3 H), 7.1–7.0 (m, 3 H), 6.7 (m, 3 H),
6.5 (m, 1 H), 6.3 (d, J = 10.4 Hz, 1 H), 6.3 (d, J = 10.5 Hz, 1 H), 5.3–5.2 (m, 1 H), 4.1–4.0 (m, 1 H), 2.2–1.7 (m, 4 H), 1.3 (s, 4.5
H), 1.3 (s, 4.5 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 173.3, 173.3, 169.8, 169.8, 162.8 (t, J = 28.9 Hz), 146.6, 146.4, 135.2, 135.2, 135.1, 128.7, 128.6, 128.6, 128.0, 117.1,
117.1, 115.8 (dd, J = 257.7, 255.5 Hz), 115.8 (dd, J = 260.6, 253.7 Hz), 113.6, 80.8, 58.1 (dd, J = 26.8, 22.2 Hz), 57.8 (dd, J = 28.0, 21.8 Hz), 52.8, 30.9, 30.9, 27.4, 25.9, 25.9.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.5 (dd, J = 252.7, 8.3 Hz, 0.5 F), –108.47 (dd, J = 251.6, 10.5 Hz, 0.5 F), –115.8 (dd, J = 251.6, 18.8 Hz, 0.5 F), –117.3 (dd, J = 252.7, 20.2 Hz, 0.5 F).
MS (EI): m/z = 461 [M]+.
HRMS (EI): m/z [M]+ calcd for C24H29F2N3O4: 461.2126; found: 461.2131.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-cysteinate (3r)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-cysteinate (3r)
Eluent: EtOAc/hexane (1:4); yield: 58.1 mg (74%); dr 1:1.1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 9.1 (d, J = 8.2 Hz, 0.48 H), 9.0 (d, J = 7.8 Hz, 0.52 H), 7.5 (m, 2 H), 7.4–7.3 (m, 3 H), 7.0 (m, 2 H), 6.7 (m, 2 H), 6.5
(m, 1 H), 6.3 (d, J = 10.5 Hz, 0.52 H), 6.3 (d, J = 10.4 Hz, 0.48 H), 5.4–5.2 (m, 1 H), 4.5–4.4 (m, 1 H), 3.5 (s, 1.44 H), 3.5 (s,
1.56 H), 2.9–2.7 (m, 2 H), 2.4 (t, J = 8.5 Hz, 0.52 H), 2.2 (t, J = 8.7 Hz, 0.48 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 169.6, 162.9 (t, J = 28.9 Hz), 162.9 (t, J = 29.8 Hz), 146.6, 146.4, 135.1, 135.0, 128.7, 128.6, 128.0, 117.2, 117.2, 115.9
(dd, J = 260.6, 254.2 Hz), 115.9 (dd, J = 257.4, 257.4 Hz), 113.5, 58.0 (dd, J = 27.1, 21.2 Hz), 57.8 (dd, J = 26.8, 21.1 Hz), 54.9, 54.8, 52.1, 24.5, 24.5.
19F NMR (DMSO-d
6, 376 MHz): δ = –107.1 (dd, J = 251.2, 8.7 Hz, 0.52 F), –108.2 (dd, J = 251.8, 9.8 Hz, 0.48 F), –116.0 (dd, J = 251.8, 18.8 Hz, 0.48 F), –117.4 (dd, J = 251.2, 20.6 Hz, 0.52 F).
MS (EI): m/z = 394 [M]+.
HRMS (EI): m/z [M]+ calcd for C19H20F2N2O3S: 394.1163; found: 394.1158.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-methioninate (3s)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-l-methioninate (3s)
Eluent: EtOAc/hexane (3:7); yield: 60.9 mg (71%); dr 1:1.1; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 9.0 (d, J = 7.8 Hz, 0.52 H), 8.9 (d, J = 7.8 Hz, 0.48 H), 7.5 (m, 2 H), 7.4–7.3 (m, 3 H), 7.0 (m, 2 H), 6.7 (m, 2 H), 6.5
(m, 1 H), 6.3 (d, J = 10.7 Hz, 0.52 H), 6.3 (d, J = 10.8 Hz, 0.48 H), 5.4–5.2 (m, 1 H), 4.5–4.4 (m, 1 H), 3.6 (s, 1.57 H), 3.6 (s,
1.43 H), 2.4–1.8 (m, 7 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 171.1, 171.0, 163.0 (t, J = 28.9 Hz), 162.9 (t, J = 29.8 Hz), 146.6, 146.4, 135.2, 135.2, 135.0, 128.7, 128.7, 128.6, 128.0, 117.2,
117.1, 115.9 (dd, J = 255.3, 254.3 Hz), 115.9 (dd, J = 261.0, 256.4 Hz), 113.4, 113.4, 58.2–57.6 (m), 52.0, 52.0, 50.9, 50.9, 29.9, 29.8,
29.3, 29.2, 14.3, 14.2.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.7 (dd, J = 251.1, 7.9 Hz, 0.48 F), –109.4 (dd, J = 250.7, 10.8 Hz, 0.52 F), –115.1 (dd, J = 250.7, 18.8 Hz, 0.52 F), –117.9 (dd, J = 251.1, 21.3 Hz, 0.48 F).
MS (EI): m/z = 422 [M]+.
HRMS (EI): m/z [M]+ calcd for C21H24F2N2O3S: 422.1476; found: 422.1475.
Methyl (S)-2-[2,2-Difluoro-3-phenyl-3-(phenylamino)propanamido]-2-phenylacetate (3u)
Methyl (S)-2-[2,2-Difluoro-3-phenyl-3-(phenylamino)propanamido]-2-phenylacetate (3u)
Eluent: EtOAc/hexane (1:4); yield: 68.7 mg (81%); dr 1:2; colorless solid.
1H NMR (DMSO-d
6, 400 MHz): δ = 9.4 (d, J = 7.3 Hz, 0.33 H), 9.3 (d, J = 7.3 Hz, 0.67 H), 7.5–7.4 (m, 2 H), 7.4–7.2 (m, 8 H), 7.0 (m, 2 H), 6.7 (m, 2 H),
6.5 (m, 1 H), 6.4 (m, 1 H), 5.5 (m, 1 H), 5.4–5.2 (m, 1 H), 3.6 (s, 1 H), 3.6 (s,
2 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 169.8, 162.6 (t, J = 28.9 Hz), 146.5, 146.3, 135.4, 135.3, 135.2, 135.0, 128.7, 128.6, 128.6, 128.3,
128.3, 128.1, 128.0, 127.9, 127.6, 127.6, 117.1, 115.8 (dd, J = 259.6, 253.8 Hz), 113.5, 113.4, 57.8 (dd, J = 27.8, 22.3 Hz), 56.2, 56.1, 52.3, 52.3.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.6 (dd, J = 250.7, 7.9 Hz, 0.67 F), –107.0 (dd, J = 252.5, 8.1 Hz, 0.33 F), –116.3 (d, J = 252.5, 20.0 Hz, 0.37 F), –117.0 (dd, J = 250.7, 21.4 Hz, 0.67 F).
MS (EI): m/z = 424 [M]+.
HRMS (EI): m/z [M]+ calcd for C24H22F2N2O3: 424.1598 found: 424.1607.
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-glycylglycylglycinate (3v)
Methyl [2,2-Difluoro-3-phenyl-3-(phenylamino)propanoyl]-glycylglycylglycinate (3v)
This product was purified without flash column chromatography. The reaction mixture
was diluted with CHCl3, then the precipitated solid was collected via suction filtration. The filtrate was
washed with cold EtOAc; yield: 75.9 mg (82%); colorless solid; mp 206.0–207.0 °C.
1H NMR (DMSO-d
6, 400 MHz): δ = 8.8 (t, J = 5.5 Hz, 1 H), 8.2 (t, J = 5.7 Hz, 1 H), 8.1 (t, J = 5.7 Hz, 1 H), 7.5 (m, 2 H), 7.4–7.3 (m, 3 H), 7.0 (m, 2 H), 6.7 (m, 2 H), 6.5 (m,
1 H), 6.3 (d, J = 10.5 Hz, 1 H), 5.3 (ddd, J = 20.6, 10.5, 8.7 Hz, 1 H), 3.9–3.7 (m, 6 H), 3.6 (s, 3 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 170.7, 169.6, 168.6, 163.7 (t, J = 28.9 Hz), 147.1, 135.8, 129.4, 129.3, 128.6, 117.9, 116.6 (dd, J = 260.6, 254.3 Hz), 114.3, 58.7 (dd, J = 27.9, 22.1 Hz), 52.2, 42.6, 42.3, 41.1.
19F NMR (DMSO-d
6, 376 MHz): δ = –106.6 (dd, J = 251.2, 8.7 Hz, 1 F), –117.8 (dd, J = 251.2, 20.6 Hz, 1 F).
MS (EI): m/z = 462 [M]+.
HRMS (EI): m/z [M]+ calcd for C22H24F2N4O5: 462.1715; found: 462.1716.
Peptide Elongation Procedure for the Synthesis of Tripeptides 6
Peptide Elongation Procedure for the Synthesis of Tripeptides 6
Methyl (3-Amino-2,2-difluoro-3-phenylpropanoyl)glycinate (5)
Methyl (3-Amino-2,2-difluoro-3-phenylpropanoyl)glycinate (5)
To a vial containing difluoro-β-lactam 2b (145 mg, 0.5 mmol) and glycine methyl ester hydrochloride (126 mg, 1.0 mmol) in TFE
(2.5 mL) was added DIPEA (0.26 mL, 1.5 mmol) at r.t. Then, the mixture was stirred
at r.t. for 2 h, poured into H2O, and extracted with EtOAc. The combined organic phases were washed with brine, dried
(MgSO4), and concentrated in vacuo. The crude fluorinated dipeptide 4 was used to the oxidative deprotection reactions without further purification. To
a vial containing the crude dipeptide 4 in MeCN (10 mL) was added a solution of ceric ammonium nitrate (548 mg, 1.0 mmol)
in H2O (1.1 mL) at 0 °C over 10 min under air. The mixture was stirred at r.t. for 2 h.
The mixture was poured into sat. aq NaHCO3, and extracted with EtOAc. The combined organic phases were washed with sat. aq Na2SO3 (2 ×) and brine, dried (MgSO4), and concentrated in vacuo. The crude mixture was purified by flash column chromatography
(70% EtOAc in hexane) to give the pure product 5 as a colorless liquid; yield: 77 mg (70% based on 2b).
1H NMR (CDCl3, 400 MHz): δ = 7.4–7.3 (m, 5 H), 7.1 (br s, 1 H), 4.6 (dd, J = 16.3, 10.2 Hz, 1 H), 4.1 (dd, J = 18.3, 5.3 Hz, 1 H), 3.9 (dd, J = 18.3, 5.2 Hz, 1 H), 3.7 (s, 3 H), 1.8 (br s, 2 H).
13C{1H} NMR (CDCl3, 100 MHz): δ = 169.1, 163.9 (t, J = 29.4 Hz), 136.0, 128.6, 128.5, 128.0, 116.0 (dd, J = 257.7, 255.8 Hz), 57.7 (dd, J = 25.0, 23.1 Hz), 52.6, 41.0.
19F NMR (CDCl3, 376 MHz): δ = –111.9 (dd, J = 255.0, 10.1 Hz, 1 F), –118.7 (dd, J = 255.0, 16.3 Hz, 1 F).
MS (EI): m/z = 272 [M]+.
HRMS (EI): m/z [M]+ calcd for C12H14F2N2O3: 272.0972; found: 272.0979.
Methyl (3-[2-({[(9H-Fluoren-9-yl)methoxy]carbonyl}amino)-acetamido]-2,2-difluoro-3-phenylpropanoyl)glycinate
(6)
Methyl (3-[2-({[(9H-Fluoren-9-yl)methoxy]carbonyl}amino)-acetamido]-2,2-difluoro-3-phenylpropanoyl)glycinate
(6)
To a vial containing dipeptide 5 (54 mg, 0.2 mmol), Fmoc-glycine (62 mg, 0.21 mmol), and HOBt (29.7 mg, 0.22 mmol)
in DMF (1 mL) was added EDC (42 mg, 0.22 mmol) in DMF (1.5 mL) at r.t. Then, the mixture
was stirred at r.t. for 22 h. The mixture was poured into aq 10% HCl and extracted
with EtOAc. The combined organic phases were washed with aq 10% HCl, sat. aq NaHCO3 (2 ×) and brine, dried (MgSO4), and concentrated in vacuo. The obtained solid was collected by suction filtration
and washed with cold Et2O to give the pure product 6 as a colorless solid; yield: 88.6 mg (80%); mp 185.5–189.0 °C.
1H NMR (DMSO-d
6, 400 MHz, 80 °C): δ = 8.9 (br s, 1 H), 8.6 (br d, J = 9.6 Hz, 1 H), 7.8 (m, 2 H), 7.7 (m, 2 H), 7.4–7.2 (m, 10 H), 5.7 (td, J = 14.8, 9.8 Hz, 1 H), 4.3–4.1 (m, 3 H), 3.9–3.7 (m, 4 H), 3.6 (s, 3 H).
13C{1H} NMR (DMSO-d
6, 100 MHz): δ = 168.9, 168.9, 162.7 (t, J = 28.9 Hz), 156.3, 143.7, 140.6, 134.1, 128.4, 128.2, 128.1, 127.5, 126.9, 125.1,
119.9, 115.3 (t, J = 257.2 Hz), 65.6, 53.7 (t, J = 24.1 Hz), 51.7, 46.5, 43.0, 40.6.
19F NMR (DMSO-d
6, 376 MHz, at 80 °C): δ = –111.1 (s, 2 F).
MS (FAB): m/z = 552 [M + H]+.
HRMS (FAB): m/z [M + H]+ calcd for C29H28F2N3O6: 552.1946; found: 552.1946.
Kinetic Study on the Stepwise Synthesis of 3a via Alcoholysis Intermediate (Scheme
[2])
Kinetic Study on the Stepwise Synthesis of 3a via Alcoholysis Intermediate (Scheme
[2])
To a vial containing difluoro-β-lactam 2a (51.9 mg, 0.2 mmol) in the corresponding alcoholysis solvent (0.3 mL) was added DIPEA
(0.035 mL, 0.2 mmol) at r.t. and stirred at r.t. for 2 h. The full conversion of 2a to 7 or 8 was monitored by TLC analysis. To the reaction mixture were added glycine methyl
ester hydrochloride (50.0 mg, 0.4 mmol) and DIPEA (0.07 mL, 0.4 mmol) and the mixture
was stirred at r.t. for 0.5 h. The mixture was poured into H2O and then extracted with EtOAc. The combined organic phases were washed with brine,
dried (MgSO4), and concentrated in vacuo. The crude mixture was purified with flash column chromatography
to give the pure product 3a.
Alcoholysis of 2a for the Structural Determination of Intermediates 7 and 8
Alcoholysis of 2a for the Structural Determination of Intermediates 7 and 8
2,2,2-Trifluoroethyl 2,2-Difluoro-3-phenyl-3-(phenylamino)-propanoate (7)
2,2,2-Trifluoroethyl 2,2-Difluoro-3-phenyl-3-(phenylamino)-propanoate (7)
To a vial containing difluoro-β-lactam 2a (51.9 mg, 0.2 mmol) in TFE (0.3 mL) was added DIPEA (0.035 mL, 0.2 mmol) at r.t.
and the mixture was stirred at r.t. for 2 h. The mixture was poured into H2O and extracted with EtOAc. The combined organic phases were washed with brine, dried
(MgSO4), and concentrated in vacuo. The crude mixture was purified by flash column chromatography
(10% EtOAc in hexane) to give the pure product 7 as a colorless solid; yield: 40.9 mg (59%); mp 125.0–128.0 °C.
1H NMR (CDCl3, 400 MHz): δ = 7.42–7.35 (m, 5 H), 7.16–7.12 (m, 2 H), 6.78–6.75 (m, 1 H), 6.66–6.64
(m, 2 H), 5.14 (ddd, J = 19.9, 10.3, 7.4 Hz, 1 H), 4.64–4.46 (m, 2 H), 4.37 (d, J = 10.1 Hz, 1 H).
13C{1H} NMR (CDCl3, 100 MHz): δ = 162.3 (dd, J = 35.0, 32.5 Hz), 144.9, 133.0, 129.4, 129.1, 128.8, 128.2, 122.1 (q, J = 277.3 Hz), 119.6, 114.5, 114.4 (dd, J = 259.4, 255.9 Hz), 61.9 (q, J = 37.6 Hz,), 59.9 (dd, J = 27.2, 22.1 Hz).
19F NMR (CDCl3, 376 MHz): δ = –73.5 (t, J = 7.9 Hz, 3 F), –107.8 (dd, J = 259.2, 7.4 Hz, 1 F), –119.8 (dd, J = 259.2, 19.9 Hz, 1 F).
MS (EI): m/z = 359 [M]+.
HRMS (EI): m/z [M]+ calcd for C17H14F5NO2: 359.0945; found: 359.0942.
Methyl 2,2-Difluoro-3-phenyl-3-(phenylamino)propanoate (8)
Methyl 2,2-Difluoro-3-phenyl-3-(phenylamino)propanoate (8)
To a vial containing difluoro-β-lactam 2a (51.9 mg, 0.2 mmol) in MeOH (0.3 mL) was added DIPEA (0.035 mL, 0.2 mmol) at r.t.
and the mixture was stirred at r.t. for 2 h. The mixture was poured into H2O and extracted with EtOAc. The combined organic phases were washed with brine, dried
(MgSO4), and concentrated in vacuo. The crude mixture was purified by flash column chromatography
(5% EtOAc in hexane) to give the pure product 8 as a colorless solid; yield: 54.4 mg (93%); mp 120.5–121.5 °C.
1H NMR (CDCl3, 400 MHz): δ = 7.41–7.32 (m, 5 H), 7.14–7.10 (m, 2 H), 6.75–6.62 (m, 3 H), 5.11 (ddd,
J = 19.0, 9.6, 7.5 Hz, 1 H), 4.44 (br d, J = 9.6 Hz, 1 H), 3.81 (s, 3 H).
13C{1H} NMR (CDCl3, 100 MHz): δ = 164.0 (dd, J = 33.2, 31.3 Hz), 145.3, 133.7, 129.3, 128.9, 128.7, 128.3, 119.2, 114.5 (dd, J = 258.2, 256.2 Hz), 114.3, 60.1 (dd, J = 27.0, 22.2 Hz), 53.6.
19F NMR (CDCl3, 376 MHz): δ = –108.6 (dd, J = 257.9, 7.5 Hz, 1 F), –119.2 (dd, J = 257.9, 19.0 Hz, 1 F).
MS (EI): m/z = 291 [M]+.
HRMS (EI): m/z [M]+ calcd for C18H20F2N2O: 291.1071; found: 291.1074.
